LongBio Pharma (Suzhou) Co., Ltd. has called an extraordinary general meeting (EGM) for 10 September 2026 at 16:00 (Beijing time) in Room 302, Building 88, No. 887 Zuchongzhi Road, Zhangjiang High-Tech Park, Pudong, Shanghai.

The sole agenda item is an ordinary resolution to approve the appointment and remuneration of Mr. Xue Kailu as a non-executive director. Voting will be conducted by poll in accordance with Hong Kong Listing Rules, and results will be released on the websites of Hong Kong Exchanges and Clearing Limited and the company.

Shareholders’ register closure: 7–10 September 2026 (both dates inclusive). H-share transfer documents must be lodged with Tricor Investor Services Limited by 16:30 on 4 September 2026 to qualify for attendance and voting.

Proxy submissions: completed forms, together with notarised authorisations where applicable, must reach Tricor Investor Services Limited no later than 24 hours before the meeting (i.e., by 16:00 on 9 September 2026). Each shareholder may appoint more than one proxy, and corporate shareholders must be represented by a legally authorised person or proxy.

Current board composition (as of the notice date, 21 August 2026): • Executive Directors – Dr. Liu Heng (Chairman), Dr. Sun Bill Nai-chau, Mr. Xie Ming • Non-Executive Directors – Mr. Lin Jian, Ms. Gu Qin, Dr. Xue Di, Dr. Chen Kan • Independent Non-Executive Directors – Mr. Siu Paul Yu Hay, Mr. Ruan Tim, Mr. Yang Chun, Mr. Zhou Guofang

Shareholders attending the EGM will bear their own travel and accommodation expenses.